click below
click below
Normal Size Small Size show me how
Sympatholytics
sypatholytic drugs
| Question | Answer |
|---|---|
| alpha antagonist nonspecific | phenoxybenzamine phentolamine |
| alpha one selective antagonist | Prazosin Terazosin Doxazosin Alfuzosin Tamsulosin |
| alpha 2 selective antagonist | Yohimbine |
| Beta antagonist nonspecific | Propranolol Penbutolol Pindolol Carteolol Nadolol Sotalol Timolol |
| Beta 1 selective antagonist | butoxamine |
| mixed alpha and beta activity | Carvedilol labetalol |
| Tyrosine hydroxylase inhibitor | Metyrosine |
| phenoxybenzamine MOA, kinetics, clinical use, toxicity | MOA: ire inhib of aR, preve up of NE, block H1, AcHR, and sero receptors. Mainly blocking vasocon by a1R on vasc kine: long dur, 14-48 hrs, oral adm w/ grad increas dose use: pheochromocytoma tox: postural hypotension, reflex tachycard sedation nas n |
| phentolamine | revers a antagonist NE release via a2 presynap R block, inhibits ser, agonist at mus, H1 and H2 histamine R kine: oral availability use: pheochromocytoma, and injected in penis to treat male ED tox:"dirty drug" effects many R sys, similar tox as phe |
| Prazosin Terazosin Doxazosin Alfuzosin MOA and tox | antagonist to alpha-adrenergic receptors= prevents vasculature constriction (hypotension), Miosis (outflow of aqueous humor), relaxes SM in urinary tract tox:orthostatic hypotension, first dose syncope, palpitations, blurred vision, priapism, GI upset |
| Prazosin Terazosin Doxazosin uses | hypertension, Raynaud's phenomenon, BPH-urinary obstruction |
| Alfuzosin kinetics and use | t 1/2 5 hours use: BPH-urinary obstruction |
| Tamsulosin | a (one A) antag, a1A R are promin in prostate and less important in vasc SM contrac (does not effect BP) high bioavail, long T1/2- 9-15 hr BPH-urinary obstruction 1st dose syncope, abnormal ejaculation, headache, dizziness, sleep problems, GI-diarrhe |
| Yohimbine | alpha 2 receptor antagonist (= more norepinephrine release from sympathetic terminals) impotence (disputed) increased catechol tone via blockade of presynaptic a2 (inhibitory receptors) leading to non attenuated NE release |
| Propranolol MOA | prototype nonspecific beta receptor blocker, slow heart rate and reduce contractile force, inhibit rennin release from kidney, reduce aqueous humor secretion, bronchoconstriction, inhibit hepatic glycogenolysis, anesthetic properties |
| propranolol kinetics | oral absorption, extensive first pass metabolism, variable bioavailability half life 3-6 hours |
| propranolol clinical uses: | hypertension, glaucoma, ischemic heart disease, post-MI prophylaxis, stage fright, tremor, migraines, portal hypertension, |
| propranolol toxicity | bronchocons (avoid asthma or COPD), bradycardia, (-)ive inotropy (avoid with CHF), hypoten, arrhythmias, sedation and depres, reduce recover from hypogly (problem with diabetics), withdraw occur (taper dose), impotence, (-)ive GI effects, alter lip pan |
| Penbutolol MOA and kinetics | (ISA) Partial agonist, similar effects to propranolol, except incomplete blockade of lungs and heart function and no anesthetic action high lipid solubility (CNS effects), good bioavailability, t1/2 5 hr |
| Pindolol MOA | (ISA) Partial agonist, similar effects to propranolol, except incomplete blockade of lungs and heart functionsimilar to penbutolol, moderate lipid solubility |
| Penbutolol Pindolol use and tox: | used for hypertension and angina when less bradycardia or bronchodilation is important similar to propranolol, except less bradycardia and bronchodilation and perhaps more CNS effects |
| Carteolol MOA | (ISA) similar to penbutolol low lipid solubility, otherwise similar to penbutolol topical drops for glaucoma, similar topical beta blockers (timolol, betaxolol, levobunolol, metipranolol) |
| Carteolol Nadolol toxicity | similar to penbutolol except less CNS effects |
| Nadolol Sotalol Timolol MOA | similar to propranolol without anesthetic action tox: similar to propranolol |
| Nadolol | long duration, 14-24 hours, low lipid solubility portal hypertension (w. Isosorbide mononitrate) |
| Sotalol | as above but w/ t1/2 12 hrs. Supraventricular arrhythmias |
| Timolol | moderate solubility, t1/2 4-5 hours topical glaucoma treatment |
| butoxamine | blockade of beta two receptors does nothing but produce bronchoconstriction no clinical value bronchoconstriction |
| Metyrosine | inhibits the rate limiting enzyme (tyrosine hydroxylase) necessory for all catecholamine synthesis pheochromocytoma extrapyramidal symptoms (loss of dopamine), orthostatic hypotension (loss of sympathetic control of vessels), crystalluria |
| Acebutolol | (ISA) more selective at beta 1 with partial agonist activity, anesthetic effects low lipid solubility, otherwise similar to penbutolol hypertension, angina, |